| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $4,551,754 | 46 | 100 |
| Palasis Maria | director | 0 | $0 | 1 | $41,552 | $-41,552 |
| Lezack Adam | director | 0 | $0 | 3 | $62,680 | $-62,680 |
| Russell Steven Jon | Chief Medical Officer | 0 | $0 | 4 | $176,656 | $-176,656 |
| Jones Christy | director | 0 | $0 | 4 | $228,214 | $-228,214 |
| Mensinger Mike | Chief Product Officer | 0 | $0 | 8 | $596,922 | $-596,922 |
| Saint Sean | President & CEO | 0 | $0 | 5 | $786,341 | $-786,341 |
| Feider Stephen | Chief Financial Officer | 0 | $0 | 7 | $1.03M | $-1.03M |
| Hopman Mark | Chief Commercial Officer | 0 | $0 | 14 | $1.63M | $-1.63M |
Beta Bionics, Inc. is a commercial-stage medical technology company dedicated to inventing, developing, and bringing to market solutions that improve the health and quality of life for individuals with diabetes who depend on insulin. The company's flagship product, the iLet Bionic Pancreas, is an automated insulin delivery system currently available for treating type 1 diabetes in adults and children aged six and older. In addition to its existing offering, Beta Bionics is actively developing several new innovations: a Patch Pump, designed as a …
Over the last 12 months, insiders at Beta Bionics, Inc. have bought $0 and sold $4.55M worth of Beta Bionics, Inc. stock.
On average, over the past 5 years, insiders at Beta Bionics, Inc. have bought $0 and sold $3.18M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
| 2026-10-27 | Sale | Mensinger Mike | Chief Product Officer | 2,650 0.0061% | $22.00 | $58,300 | -21.69% | |
| 2026-10-26 | Sale | Hopman Mark | Chief Commercial Officer | 821 0.0018% | $20.00 | $16,420 | -16.31% | |
| 2026-10-14 | Sale | Hopman Mark | Chief Commercial Officer | 775 0.0018% | $17.35 | $13,446 | +4.68% | |
| 2026-10-01 | Sale | Hopman Mark | Chief Commercial Officer | 370 0.0008% | $18.96 | $7,015 | -5.99% | |
| 2026-09-22 | Sale | Jones Christy | director | 6,430 0.015% | $23.00 | $147,890 | -20.04% | |
| 2026-09-16 | Sale | Mensinger Mike | Chief Product Officer | 2,650 0.0058% | $22.00 | $58,300 | -15.46% | |
| 2026-09-16 | Sale | Hopman Mark | Chief Commercial Officer | 30,779 0.0621% | $20.13 | $619,640 | -15.46% | |
| 2026-09-14 | Sale | Hopman Mark | Chief Commercial Officer | 775 0.0016% | $15.52 | $12,028 | +13.03% | |
| 2026-09-09 | Sale | Hopman Mark | Chief Commercial Officer | 35,994 0.0848% | $18.46 | $664,550 | +6.95% | |
| 2026-09-03 | Sale | Saint Sean | President & CEO | 5,641 0.0126% | $20.08 | $113,259 | -5.87% | |
| 2026-09-02 | Sale | Saint Sean | President & CEO | 16,867 0.0369% | $19.11 | $322,381 | -2.83% | |
| 2026-09-02 | Sale | Mensinger Mike | Chief Product Officer | 4,375 0.0096% | $19.11 | $83,620 | -2.83% | |
| 2026-09-02 | Sale | Russell Steven Jon | Chief Medical Officer | 4,221 0.0092% | $19.11 | $80,676 | -2.83% | |
| 2026-09-02 | Sale | Feider Stephen | Chief Financial Officer | 6,675 0.0146% | $19.11 | $127,580 | -2.83% | |
| 2026-09-02 | Sale | Hopman Mark | Chief Commercial Officer | 5,327 0.0117% | $19.11 | $101,815 | -2.83% | |
| 2026-06-29 | Sale | Feider Stephen | Chief Financial Officer | 4,896 0.011% | $17.03 | $83,381 | +3.65% | |
| 2026-06-26 | Sale | Feider Stephen | Chief Financial Officer | 5,104 0.0116% | $17.05 | $87,006 | +4.76% | |
| 2026-06-24 | Sale | Hopman Mark | Chief Commercial Officer | 1,258 0.0031% | $15.01 | $18,880 | +19.48% | |
| 2026-06-24 | Sale | Jones Christy | director | 1,406 0.0035% | $15.00 | $21,090 | +19.48% | |
| 2026-06-04 | Sale | Hopman Mark | Chief Commercial Officer | 275 0.0005% | $12.31 | $3,385 | +24.62% |
| Increased Positions | 108 | +97.3% | 9M | +17.74% |
| Decreased Positions | 46 | -41.44% | 9M | -19.56% |
| New Positions | 47 | New | 6M | New |
| Sold Out Positions | 16 | Sold Out | 6M | Sold Out |
| Total Postitions | 173 | +55.86% | 47M | -1.82% |